Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label TX000045 study in pulmonary hypertension due to interstitial lung disease
2026-525810-80-00Phase 2Authorised
- Sponsor
- Tectonic Therapeutic
- Start
- Sep 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Hormonal Peptides → Native Peptides → Peptides, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 7
01
Overview
Phase 2, open-label, single-arm trial of TX000045 in pulmonary hypertension associated with interstitial lung disease (PH-ILD), sponsored by Tectonic Therapeutic. Primary endpoints: Mean change from baseline in pulmonary vascular resistance, Incidence of adverse events and 1 more. Planned start Sep 2026; status: authorised.
02
Drugs
TX000045
03
Conditions
pulmonary hypertension associated with interstitial lung disease (PH-ILD)
Beyond the preview
Go deeper on 2026-525810-80-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525810-80-00.